Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: A transmission dynamic modeling approach

Value in Health

Volumn 15, Issue 1 SUPPL., 2012, Pages

  Bin Chia Wu, David ^a   Chang, Chee Jen ^b   Huang, Yu Chering ^c   Wen, Yu Wen ^b   Wu, Chia Ling ^b   Fann, Cathy Shen Jang ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

13 valent pneumococcal conjugate vaccine (PCV13); cost effectiveness; herd effect; Streptococcus pneumoniae; transmission dynamic model

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEATH; DISEASE MODEL; DISEASE TRANSMISSION; DRUG COST; ECONOMIC ASPECT; HEALTH PROGRAM; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STREPTOCOCCUS PNEUMONIAE; TAIWAN; VACCINATION; WORLD HEALTH ORGANIZATION;

COST-BENEFIT ANALYSIS; HUMANS; MODELS, BIOLOGICAL; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; REPRODUCIBILITY OF RESULTS; TAIWAN;

EID: 84862907594     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.11.013     Document Type: Conference Paper

References (54)

1. K.L. O'Brien, L.J. Wolfson, J.P. Watt Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates Lancet 374 2009 893 902
2. C.J.L. Murray, A.D. Lopez The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 1996 Harvard School of Public Health for the World Health Organization and the World Bank Cambridge, MA
3. L.C. Bravo Members of the Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) Working Group Overview of the disease burden of invasive pneumococcal disease in Asia Vaccine 27 2009 7282 7291
4. T.Y. Lin, N.K. Shah, D. Brooks Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region Vaccine 28 2010 7589 7605
5. Y.Y. Chen, S.M. Yao, C.Y. Chou Surveillance of invasive Streptococcus pneumoniae in Taiwan, 20022003 J Med Microbiol 55 2006 1109 1114
6. O.S. Levine, M.D. Knoll, A. Jones Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions Curr Opin Infect Dis 23 2010 236 241
7. S.H. Yeh, A. Gurtman, D.C. Hurley Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers Pediatrics 126 2010 e493 e505
8. C.G. Whitney, M.M. Farley, J. Hadler Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N Engl J Med 348 2003 1737 1746 (Pubitemid 36514704)
9. S. Black, H. Shinefield, R. Baxter Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente Pediatr Infect Dis J 23 2004 485 489 (Pubitemid 38802290)
10. C.A. Lexau, R. Lynfield, R. Danila Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine JAMA 294 2005 2043 2051 (Pubitemid 41539937)
11. Centers for Disease Control and Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal diseaseUnited States, 19982003 MMWR Morb Mortal Wkly Rep 54 2005 893 897
12. D.J. Isaacman, D.R. Strutton, E.A. Kalpas The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine [review] Clin Ther 30 2008 341 357 (Pubitemid 351474375)
13. K.L. O'Brien, L.H. Moulton, R. Reid Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial Lancet 362 2003 355 361 (Pubitemid 36945058)
14. A. Frank, J. Sonnenberg, R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338
15. F. Asensi, M. De Jose, M. Lorente A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain Value Health 7 2004 36 51 (Pubitemid 38186283)
16. L. Tilson, C. Usher, K. Bulter Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland Value Health 11 2008 898 903
17. H.S. Sohn, D.C. Suh, E. Jang, J.W. Kwon Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea J Manag Care Pharm 16 2010 32 45
18. K.K. Lee, F. Rinaldi, M.K. Chan Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong Value Health 12 Suppl. 3 2009 S42 S48
19. W.J. Edmunds, G.F. Medley, D.J. Nokes Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective Stat Med 18 1999 3263 3282
20. R.M. Anderson, R.M. May Infectious Diseases of Humans 1991 Oxford University Press Oxford
21. M. Brisson, W.J. Edmunds Economic evaluation of vaccination programs: the impact of herd-immunity Med Decis Making 23 2003 76 82 (Pubitemid 36133362)
22. E.H. Elbasha, E.J. Dasbach, R.P. Insinga Age-based programs for vaccination against HPV Value Health 12 2009 697 707
23. A. Melegaro, Y.H. Choi, R. George Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease BMC Infect Dis 10 2010 90
24. T. Van Effelterre, M.R. Moore, F. Fierens A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination Vaccine 28 2010 3650 3660
25. S.J. Snedecor, D.R. Strutton, V. Ciuryla Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations Vaccine 27 2009 4694 4703
26. Ministry of Interior in Taiwan Statistical yearbook of interior www.moi.gov.tw/ Accessed October 12, 2010
27. Centers for Disease Control, Department of Health Statistics 837 of Communicable Diseases and Surveillance Report, Republic of China 2007 2008 Centers for Disease Control, Department of Health Taiwan
28. S. Black, H. Shinefield, B. Fireman Northern California Kaiser Permanente Vaccine Study Center Group Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children Pediatr Infect Dis J 19 2000 187 195 (Pubitemid 30167436)
29. Y.C. Hsieh, P.Y. Lin, C.H. Chiu National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential Vaccine 27 2009 5513 5518
30. J. Hansen, S. Black, H. Shinefield Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs Pediatr Infect Dis J 25 2006 779 781 (Pubitemid 44325778)
31. J. Eskola, T. Kilpi, A. Palmu Efficacy of a pneumococcal conjugate vaccine against acute otitis media N Engl J Med 344 2001 403 409 (Pubitemid 32128672)
32. R. Prymula, P. Peeters, V. Chrobok Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study Lancet 367 2006 740 748 (Pubitemid 43326292)
33. M.R. Gold, J.E. Siegel, L.B. Russell Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
34. Directorate General of Budget, Accounting and Statistics, Executive Yuan, Taiwan Summary of earning and productivity statistics in Taiwan area win.dgbas.gov.tw/fies/doc/result/97/a13/233-234.xls Accessed October 10, 2010
35. Pediatric/VFC Vaccine Price List www.cdc.gov/vaccines/programs/vfc/cdc- vac-price-list.htm#pediatric Accessed October 10, 2010
36. S. Esposito, L. Pugni, S. Bosis Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 2, 5 and 11 months post-natally to pre- and full-term infants Vaccine 23 2005 1703 1708 (Pubitemid 40215704)
37. H. Kyhty, H. Ahman, K. Eriksson Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5, and 12 months of age Pediatr Infect Dis J 24 2005 108 114 (Pubitemid 40250767)
38. World Health Organization World Health Organization cost-effectiveness threshold values www.who.int/choice/en/ Accessed September 12, 2010
39. J.A. Salomon, M.C. Weinstein, S.J. Goldie Taking account of future technology in cost-effectiveness analysis BMJ 329 2004 733 736 (Pubitemid 39312701)
40. C. Evans, M. Tavakoli, B. Crawford Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal Health Care Manag Sci 7 2004 43 49 (Pubitemid 39024064)
41. A. Briggs, M. Sculpher, M. Buxton Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis Health Econ 3 1994 95 104
42. E.F. Halpern, M.C. Weinstein, M.G. Hunink Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients Med Decis Making 20 2000 314 322 (Pubitemid 30470727)
43. E. Fenwick, B.J. O'Brien, A. Briggs Cost-effectiveness acceptability curvesfacts, fallacies and frequently asked questions Health Econ 13 2004 405 415 (Pubitemid 38660390)
44. D.J. Earn, P. Rohani, B.M. Bolker A simple model for complex dynamical transitions in epidemics Science 287 2000 667 670 (Pubitemid 30070917)
45. R. Gani, S. Leach Transmission potential of smallpox in contemporary populations Nature 414 2001 748 751 (Pubitemid 34000771)
46. A. Scherer, A. McLean Mathematical models of vaccination Br Med Bull 62 2002 187 199 (Pubitemid 34832480)
47. C.E. Mills, J.M. Robins, M. Lipsitch Transmissibility of 1918 pandemic influenza Nature 432 2004 904 906 (Pubitemid 40037151)
48. Bureau of National Health Insurance, Taiwan The National Health Insurance Annual Statistical Report 2004 www.nhi.gov.tw Accessed October 12, 2010
49. S.Y. Kim, G. Lee, S.J. Goldie Economic evaluation of pneumococcal conjugate vaccination in the Gambia BMC Infect Dis 10 2010 260
50. J.D. Kellner, O.G. Vanderkooi, J. MacDonald Changing epidemiology of invasive pneumococcal disease in Canada, 19982007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study Clin Infect Dis 49 2009 205 212
51. L.A. Hicks, L.H. Harrison, B. Flannery Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 19982004 J Infect Dis 196 2007 1346 1354 (Pubitemid 351412007)
52. T.R. Talbot, K.A. Poehling, T.V. Kartert Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine Clin Infect Dis 39 2004 641 648 (Pubitemid 39180434)
53. E.D. McIntosh, P. Conway, J. Willingham Pneumococcal pneumonia in the UKhow herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV) Vaccine 23 2005 1739 1745 (Pubitemid 40215709)
54. Centers for Disease Control, Department of Health, Taiwan www.cdc.gov.tw/public/Data/031517593171.pdf Accessed October 12, 2010